Claims for Patent: 9,810,696

Summary for Patent: 9,810,696

Title:	PGLYRP2 biomarker in idiopathic pneumonia syndrome
Abstract:	A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.
Inventor(s):	Chance; Mark (Chagrin Falls, OH), Cooke; Kenneth (Solon, OH), Schlatzer; Daniela (Lakewood, OH)
Assignee:	Case Western Reserve University (Cleveland, OH)
Application Number:	14/571,067
Patent Claims:	1. A method for identifying and treating idiopathic pneumonia syndrome (IPS) progression in a subject following allogeneic hematopoietic stem cell transplantation, the method comprising: obtaining a biological sample from the subject, wherein the biological sample comprises a sample of blood, plasma, serum, or bronchoalveolar lavage fluid, wherein the subject has received the allogeneic hematopoietic stem cell transplantation; determining in the biological sample a level of PGLYRP2; comparing the determined level of PGLYRP2 to a control level prior to transplantation; identifying the IPS as progressing if the level of PGLYRP2 determined is decreased at least 5% compared to the control level; and administering a therapeutically effective amount at least one TNF-.alpha. inhibitor to the subject with progressive IPS. 2. The method of claim 1, wherein IPS in the subject is identified as progressing when the decrease in the level of PGLYRP2 is at least 20% in the determined level compared to the control level. 3. The method of claim 1, wherein the IPS is a subtype of idiopathic pneumonia syndrome that is responsive to treatment by a TNF-.alpha. inhibitor, wherein the TNF-.alpha. inhibitor is selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab pegol, gohmumab (simponi), lenercept, semapimod, pentoxifylline, thalidomide, and benzopyranes.

Details for Patent 9,810,696

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2029-06-01
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2029-06-01
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2029-06-01
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2029-06-01
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2029-06-01
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2029-06-01